/

PRLD

Prelude Therapeutics IncorporatOpen

3.55−0.19 −5.08%USD

NasdaqGS · as of Oct 13, 15:48 ET · 15m delay

Open

3.74

Prev close

3.74

Day range

3.433.89

52-week range

1.166.83

Volume

588.18K1.24×

Mkt cap

283.30M

P/E ttm

—

Fwd P/E

-6.45

EPS ttm

-0.7300

Div yield

0.00%

Earnings

Aug 11, 2026

From 52w high

−48.02%

Price Chart

Yahoo Finance · delayed

PRLDOct 13, 2026O 3.74H 3.89L 3.43C 3.55−0.19 (−5.08%)Vol 588.18K

SMA 504.89
SMA 2003.94

1Y change +181.75% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

PRLD Prelude Therapeutics Incorporat · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −6.82%
1 month: −22.66%
3 months: −19.13%
6 months: −19.32%
Year to date: +22.41%
1 year: +184.00%

Valuation & ownership

Market cap: 283.30M
Enterprise value: 251.09M
P/E (ttm): —
Forward P/E: -6.45
PEG ratio: —
Price / book: 2.73
Price / sales (ttm): 12.63
EV / EBITDA: -3.89
EPS (ttm): -0.7300
EPS (forward): -0.5501
Beta (5y monthly): 0.96
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 65.08M
Float: 22.06M
Short % of float: 18.07%
Short ratio (days): 8.95
Held by insiders: 13.76%
Held by institutions: 76.42%
Avg volume (3m): 473.60K
50-day average: 4.91
200-day average: 3.94
52-week change: +184.00%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 30.5
vs 50-day SMA: −27.40%
vs 200-day SMA: −9.99%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 8.61%
Realised vol (20d, ann.): 65.6%
From 52-week high: −48.02%
From 52-week low: +206.03%

ANR

Analyst Consensus

5 analysts

Consensus

Strong buy

1.40 on a 1 (strong buy) – 5 (sell) scale

Mean target

9.20

+159.15% implied

Low 6.00Median 10.00High 12.00

Recommendation trend

Now5 / 0 / 0
1m ago5 / 0 / 0

DES

About Prelude Therapeutics Incorporat

Yahoo Finance profile

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Sector: Healthcare
Industry: Biotechnology
Employees: 79
Headquarters: Wilmington, DE, United States
Website: preludetx.com
Officers: Dr. Krishna Vaddi D.V.M., Ph.D. Founder, CEO & Director
Mr. Bryant David Lim J.D. CFO, Chief Legal Officer & Corporate Secretary
Dr. Peggy A. Scherle Ph.D. Chief Scientific Officer
Ms. Aimee Crombie Ph.D. Senior VP and Head of Strategic Planning & Operations

SEAS

Seasonality · PRLD

2020–2026 · monthly returns

Strongest month Dec +23.29%Weakest month Oct −17.09%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-36.2	49.2	23.9	52.9	-25.0	36.0	-13.7	21.7	-30.2	-9.2			+22.4%
2025	-13.7	-31.0	1.2	25.0	-7.7	-8.7	-3.6	55.1	19.0	10.4	5.7	72.6	+127.5%
2024	-23.2	31.1	10.2	-20.5	2.1	-1.0	67.2	-18.4	-60.2	-42.0	-12.5	21.4	−70.1%
2023	5.6	-11.3	0.7	13.3	-13.6	-19.4	-13.1	-4.6	-17.2	-45.3	95.9	29.0	−29.3%
2022	-20.2	-11.1	-21.9	-33.5	-8.5	24.3	-4.2	44.0	-8.2	1.2	-0.3	-9.4	−51.5%
2021	-9.2	-4.0	-30.5	-4.4	-16.1	-17.6	11.9	11.4	-12.4	-43.7	-18.7	-12.9	−82.6%
2020										16.9	46.1	39.0	+137.5%

INSD

Insider Activity · PRLD

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Apr 20, 2026	Bonita David P.Director and Beneficial Owner of more than 10% of a Class of Security	Purchase at price 4.44 per share.	2.82M	$12.50M
Apr 20, 2026	Orbimed Advisors, L.L.C.Beneficial Owner of more than 10% of a Class of Security	Purchase at price 4.44 per share.	2.82M	$12.50M
Oct 2, 2025	Huang JanePresident	—	9.4K	—
Jul 2, 2025	Huang JanePresident	—	9.4K	—
Apr 3, 2025	Huang JanePresident	—	9.4K	—
Mar 24, 2025	Vaddi KrishnaChief Executive Officer	Purchase at price 0.69 per share.	675K	$467.44K
Mar 24, 2025	Combs Andrew POfficer	Purchase at price 0.69 per share.	100K	$69.25K
Mar 20, 2025	Vaddi KrishnaChief Executive Officer	Purchase at price 0.73 per share.	20.4K	$14.91K
Mar 16, 2025	Vaddi KrishnaChief Executive Officer	Purchase at price 0.75 per share.	39.1K	$29.46K
Mar 12, 2025	Vaddi KrishnaChief Executive Officer	Purchase at price 0.71 - 0.72 per share.	97.5K	$69.56K
Jan 2, 2025	Huang JanePresident	—	9.4K	—
Dec 30, 2024	Vaddi KrishnaChief Executive Officer	Purchase at price 1.21 per share.	5K	$6.04K
Dec 29, 2024	Vaddi KrishnaChief Executive Officer	Purchase at price 1.20 per share.	10K	$12.00K
Dec 22, 2024	Combs Andrew POfficer	Purchase at price 1.15 - 1.37 per share.	63.1K	$85.54K
Dec 18, 2024	Lim Bryant DavidChief Financial Officer	Purchase at price 0.91 per share.	25K	$22.64K
Dec 18, 2024	Vaddi KrishnaChief Executive Officer	Purchase at price 0.89 - 0.93 per share.	106.9K	$99.33K

13F

Investors Holding PRLD

latest 13F filings of 29 followed managers

Investors holding PRLD
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$1.5M	0.00%	281.20K	+2.2%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

PRLD

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

PRLD

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Prelude Therapeutics Incorporat

Seasonality · PRLD

Insider Activity · PRLD

Congress Trades · PRLD

Investors Holding PRLD

Investors Holding PRLD

Congress Trades · PRLD

Insider Activity · PRLD

Seasonality · PRLD

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Prelude Therapeutics Incorporat

Financial Snapshot

Earnings & Dividends

News